Literature DB >> 25741635

Acute vision loss after ocriplasmin use.

Benjamin Reiss1, Lindsay Smithen, Sam Mansour.   

Abstract

PURPOSE: There have been reports in the literature of transient vision loss after ocriplasmin injection and ellipsoid layer disruption on spectral domain optical coherence tomography. The authors report a patient with transient vision loss and more prolonged ellipsoid layer dysfunction. PATIENT: The authors present a 55-year-old woman with vitreomacular traction and a small foveal schisis who received ocriplasmin injection and experienced sudden transient vision loss. Spectral domain optical coherence tomography imaging revealed significantly increased schisis, new subretinal cavity, and prolonged ellipsoid layer disruption at 9 months. DISCUSSION: Previous reports suggested that acute vision loss after ocriplasmin injection may be due to ellipsoid layer disruption. This case showed vision loss, which may due to increased foveal schisis and a new subretinal cavity on spectral domain optical coherence tomography imaging. There was little correlation between ellipsoid layer loss and visual function.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25741635     DOI: 10.1097/ICB.0000000000000128

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  2 in total

Review 1.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

2.  Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.

Authors:  Settimio Rossi; Francesco Testa; Paolo Melillo; Ada Orrico; Michele Della Corte; Francesca Simonelli
Journal:  BMC Ophthalmol       Date:  2016-07-18       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.